No category-specific facts could be extracted from this document.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company selected candidates with the qualifications, expertise and experience required to steadily execute the new medium-term management plan and enhance corporate value over the medium to long term. Regarding the CEO, the Company determined that it would be best to maintain the current executive management structure, in which Edahiro Hiromi (枝廣弘巳) and Bada Akira (馬田明), who possess extensive knowledge of the pharmaceutical wholesaling industry and trusted relationships with business partners, exercise leadership. The Company also expects Ito Masahiko (伊藤雅彦) to draw on his extensive knowledge and experience in corporate management and governance to provide advice and supervision from an independent standpoint.